Dima Kuzmin
Managing Partner at 4BIO Capital
London, England
Overview
Work Experience
Managing Partner
2014 - Current
71 investments in advanced therapies (and counting) across private and public markets. Committed to curing chronic diseases through advanced therapies.
Assistant Professor Adjunct of Medicine
2021
Pre-clinical and clinical trial design, ethics of access and reimbursement for one-shot curative therapies
Kauffman Fellow - Graduated
2023
Kauffman Fellow - Class 26
2021 - 2023
Kauffman Fellowship Program (Class 26): The Kauffman Fellowship is a two-year executive education program that identifies and develops global leaders in VC while providing a structured curriculum, peer learning, executive coaching, and networking — all with a focus on giving back and one's responsibility as a leader in venture capital. With 700+ Fellows across 50+ countries, Kauffman Fellows is the largest network of VCs and innovation leaders in the world. Each year, the organization adds a new cohort of 60 accomplished Fellows who attend this two-year program part-time, while they are investing full time.
Co-investment VC firm supporting the mission of the Kauffman Fellows
Chairman of the Board
2022
Hornet Therapeutics is a biotech company focused on developing treatments to address EBV-driven pathologies. Read our launch paper in Science here: https://www.science.org/doi/10.1126/science.adk4898
Chairman of the Board
2024
Board Member
2020 - 2024
Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) This linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.
Chairman of the Board
2023
Board Member
2021
Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need. The company’s mission is to use optogenetics to restore vision, agnostic of genetic mutation for patients with inherited retinal diseases.
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Raised $114,000,000.00 from California Institute for Regenerative Medicine and California Institute for Regenerative Medicine.
Board Member
2021
Headquartered in Greater Philadelphia, Code Bio is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases.
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
Raised $85,000,000.00 from UPMC Enterprises, Amgen Ventures, CureDuchenne Ventures, New Enterprise Associates, 4BIO Capital, UCB Ventures, Takeda Ventures, JDRF T1D Fund, Northpond Ventures and Hatteras Venture Partners.
Board Member
2020 - 2022
Based in New York City, Redpin Therapeutics is a privately-held, preclinical stage gene therapy company developing a proprietary chemogenetics platform for targeted cell therapies to address currently intractable diseases of the central nervous system. Acquired by Kriya in November 2022.
Redpin Therapeutics is a preclinical stage gene therapy company that develops chemogenetics platform designed for nervous system diseases.
Raised $17,000,000.00 from New York Ventures, Takeda Ventures, Alexandria Venture Investments, Arkin Bio Ventures, 4BIO Capital and New York Ventures.
Board Observer
2020 - 2022
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration.